CELL & GENE THERAPY INSIGHTS

Welcome to the Cell & Gene Therapy Analytics Hub

The comprehensive characterization of critical quality attributes (CQAs) for the safety and efficacy of the viral vector material produced for gene therapy trials remains a key challenge for the advanced therapies sector. Viral vector analytical development teams are required to address issues such as identification, characterization, and enumeration of undesired contaminants such as mycoplasma.

With the CMC-related requirements of the US FDA, EMA, and other major regulatory agencies still evolving and steadily increasing in stringency, it is more important than ever to harness the cutting edge in analytical tools to improve the identification and measurement of these CQAs.

Fortunately, a new generation of analytical tools designed to meet the specific needs of viral vector production is arriving, offering the enhanced speed, sensitivity, and robustness that industry requires.

The following curated collection of content offers technical and strategic insights and practical advice relating to:

  • Analytical development
  • Cell therapy manufacturing
  • Expression systems
  • Mycoplasma testing
  • Regulatory CMC
  • Residual DNA testing
  • Vector production

   Any Questions?

Content

Mycoplasma testing: regulatory guidance and strategies for cGMP cell and gene therapy manufacturing

Mycoplasma testing: regulatory guidance and strategies for cGMP cell and gene therapy manufacturing

Mike Brewer
15 December 2022
Webinar Digest
Robust quantitation of residual host cell and plasmid DNA & oncogenic fragments in HEK-based viral vector manufacturing

Robust quantitation of residual host cell and plasmid DNA & oncogenic fragments in HEK-based viral vector manufacturing

16 October 2022
FastFacts
Simplifying analytical development of viral vector production: robust and sensitive methods for common expression systems

Simplifying analytical development of viral vector production: robust and sensitive methods for common expression systems

Srinath Kashi Ranganath
16 July 2022
Innovator Insight
Removing technological barriers to efficient large-scale LV vector production

Removing technological barriers to efficient large-scale LV vector production

S Jeffers, E Jackson-Holmes, R Lopez de Maturana et al.
27 June 2022
Innovator Insight
Key factors to consider for successful cell therapy manufacturing: a case study

Key factors to consider for successful cell therapy manufacturing: a case study

2 March 2022
Podcast
Residual DNA testing in viral vector manufacture: exploring the challenges and solutions

Residual DNA testing in viral vector manufacture: exploring the challenges and solutions

Ilaria Scarfone, Mike Brewer
22 February 2022
Podcast
Expression systems for viral vector production: advantages of the Sf9 baculovirus system and simple solutions to address its specific analytical challenges

Expression systems for viral vector production: advantages of the Sf9 baculovirus system and simple solutions to address its specific analytical challenges

Yi Fang Lee, Srinath Kashi Ranganath
25 October 2021
Innovator Insight
Manufacturing and analytics for lentivirus and AAV vectors: a visual and audio guide

Manufacturing and analytics for lentivirus and AAV vectors: a visual and audio guide

21 August 2021
Infographic
Development & validation of a robust commercial solution for measuring residual kanamycin-resistant plasmid DNA

Development & validation of a robust commercial solution for measuring residual kanamycin-resistant plasmid DNA

Tania Chakrabarty
10 August 2021
FastFacts
Mycoplasma detection in cell therapy products: GMP-compliant implementation & validation of a commercial real-time PCR assay for routine quality control & lot release

Mycoplasma detection in cell therapy products: GMP-compliant implementation & validation of a commercial real-time PCR assay for routine quality control & lot release

Valentina Becherucci
21 June 2021
FastFacts

   Any Questions?